

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Docket No: **Q96012**

**Kiyotaka KUZUSHIMA et al**

Conf. No.: **1872**

Appln. No.: **10/586,852**

Group Art Unit: **1642**

Filed: **July 20, 2006**

Examiner: **Yu, Misook**

For: **EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED  
EP/CAM-SPECIFIC CTL AND USE OF THE SAME**

**STATEMENT IN SUPPORT OF SUBMISSION  
IN ACCORDANCE WITH 37 C.F.R. § 1.821**

**MAIL STOP SEQUENCE**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The following statement meets the requirements of 37 C.F.R. § 1.821.

I hereby state that the content of the computer readable copy (PatentIn Version 3.3) of the substitute Sequence Listing submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, is the same as the Substitute Sequence Listing submitted herewith.

The submission filed in accordance with 37 C.F.R. §1.821(e), (f) and (g) and §§ 1.825 (b) and (d), does not include any new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge and that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

May 27, 2009



Date:

William J. Simmons, Ph.D.